SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 7
|
records per page:
next > | last >>
|
|
pages:
1
2
3
4
5
6
7
|
presentations:
1 to
50 of
337
|
DOES HIV IMPACT COVID-19 SUSCEPTIBILITY OR SEVERITY?
(ABSTRACT
31)
Julia Del Amo
Ministry of Health, Madrid, Spain
THE IMPACT OF COVID-19 ON THE HIV PANDEMIC WORLDWIDE
(ABSTRACT
32)
Andrew D Kambugu
Makerere University, Kampala, Uganda
THE IMPACT OF COVID-19 BEYOND HIV
(ABSTRACT
33)
Helen Bygrave
International AIDS Society, London, United Kingdom
FEAR AND COVID-19: EXPERIENCES ON THE GROUND
(ABSTRACT
34)
Francois Venter
Ezintsha, Johannesburg, South Africa
FROM GENOME TO FUNCTION: PHENOTYPIC CHARACTERISATION OF PANDEMIC SARS-COV-2 VARIANTS
(ABSTRACT
23)
Volker Thiel
University of Bern, Bern, Switzerland
IMMUNE EVASION STRATEGIES BY SARS-COV-2: NSP1 AND BEYOND
(ABSTRACT
24)
Konstantin Sparrer
Ulm University, Ulm, Germany
SHARED VULNERABILITIES AND DIFFERENT COUNTERMEASURES OF HIV AND SARS-COV-2
(ABSTRACT
25)
Eric O Freed
National Cancer Institute, Frederick, MD, USA
IMMUNE RESPONSES TO SARS-COV-2
(ABSTRACT
26)
Akiko Iwasaki
Yale University, New Haven, CT, USA
SYMPOSIUM CONVENER
Wesley I Sundquist
University of Utah School of Medicine, Salt Lake City, UT, USA
LIVE-CELL IMAGING: CAPSID TRAFFICKING TO THE NUCLEUS
(ABSTRACT
19)
Barbara Müller
University Hospital Heidelberg, Heidelberg, Germany
LIVE-CELL IMAGING OF HIV-1 NUCLEAR IMPORT, UNCOATING, AND PROVIRUSES
(ABSTRACT
20)
Vinay K Pathak
National Cancer Institute, Frederick, MD, USA
VISUALIZATION OF HIV-1 CAPSID-DEPENDENT REPLICATION IN VITRO
(ABSTRACT
21)
Barbie Ganser-Pornillos
University of Virginia, Charlottesville, VA, USA
LENACAPAVIR (GS-6207): FIRST CLINICALLY ACTIVE LONG-ACTING INHIBITOR OF HIV CAPSID
(ABSTRACT
22)
Tomas Cihlar
Gilead Sciences, Inc, Foster City, CA, USA
THE POTENTIAL OF LONG-ACTING INJECTABLE DRUGS FOR PREVENTION AND TREATMENT OF TUBERCULOSIS
(ABSTRACT
27)
Eric Nuermberger
Johns Hopkins University, Baltimore, MD, USA
PREGNANCY, HIV, AND TUBERCULOSIS: CURRENT PRACTICES AND RESEARCH OPPORTUNITIES
(ABSTRACT
28)
Jyoti S Mathad
Weill Cornell Medical College, New York, NY, USA
ADVANCES IN PEDIATRIC TUBERCULOSIS PREVENTION AND TREATMENT
(ABSTRACT
29)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
IMPACT OF COVID-19 PANDEMIC ON HIV AND TUBERCULOSIS: WHO PERSPECTIVE
(ABSTRACT
30)
Souyma Swaminathan
World Health Organization, Geneva, Switzerland
SINGLE VASCULAR CELL HETEROGENEITY IN HEALTH AND DISEASE: A COVID-19 UPDATE
(ABSTRACT
49)
Peter Carmeliet
VIB KU Leuven Center for Cancer Biology, Leuven, Belgium
BODY ON FIRE: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
(ABSTRACT
50)
Elizabeth A Whittaker
Imperial College Healthcare NHS Trust, London, United Kingdom
THINK ABOUT IT: NEUROLOGIC MANIFESTATIONS OF COVID-19
(ABSTRACT
51)
Benedict D Michael
University of Liverpool, Liverpool, United Kingdom
COVID-19: CONCERNS OF THE HEART
(ABSTRACT
52)
Valentina O Puntmann
Goethe University, University Hospital Frankfurt, Frankfurt, Germany
HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY?
(ABSTRACT
42)
Lydie Trautmann
Vaccine and Gene Therapy Institute, Beaverton, OR, USA
BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS
(ABSTRACT
43)
Afam Okoye
Oregon Health & Science University, Beaverton, OR, USA
INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING
(ABSTRACT
41)
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1
(ABSTRACT
44)
Beatrice H Hahn
University of Pennsylvania, Philadelphia, PA, USA
TRIPLE DRUG ART, DUAL ART, OR JUST ART?
(ABSTRACT
45)
Jose R Arribas
Hospital Universitario La Paz, Madrid, Spain
NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT
(ABSTRACT
46)
Alexandra L Calmy
Geneva University Hospitals, Geneva, Switzerland
ARVS AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER
(ABSTRACT
47)
Moherndran Archary
University of KwaZulu-Natal, Durban, South Africa
GOT ANYTHING FOR THIS COUGH? NEW ANTIVIRALS FOR TREATMENT OF SARS-COV-2
(ABSTRACT
48)
Davey M Smith
University of California San Diego, San Diego, CA, USA
YOUNG WOMEN: ADHERENCE, EFFECT, AND RETENTION
(ABSTRACT
53)
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING PREP IN KEY POPULATIONS
(ABSTRACT
54)
Greg A Millett
amfAR, District of Columbia, DC, USA
MODELS OF DELIVERING PREP IN EAST AFRICA: INNOVATIONS AND LESSONS LEARNED
(ABSTRACT
55)
Moses R Kamya
Department of Medicine, Makerere University, Kampala, Uganda
INCORPORATING INJECTABLE PREP AND NEWER FORMULATIONS INTO LMIC
(ABSTRACT
56)
Yogan Pillay
Clinton Health Access Initiative, Pretoria, South Africa
PREP DURING PREGNANCY AND BREASTFEEDING
(ABSTRACT
66)
John Kinuthia
University of Nairobi, Nairobi, Kenya
IMPROVING ADOLESCENT PREP USE: UNDERSTANDING DEVELOPMENTAL PROCESSES AND CONTEXT
(ABSTRACT
68)
Claude A Mellins
New York State Psychiatric Institute and Columbia University, New York, NY, USA
PREP ADHERENCE INTERVENTIONS FOR ADOLESCENTS AND YOUNG ADULTS
(ABSTRACT
67)
Sybil Hosek
Stroger Hospital of Cook County, Chicago, IL, USA
IMPROVING HOW WE MARKET PREP TO YOUTH
(ABSTRACT
69)
Elzette Rousseau
University of Cape Town, Cape Town, South Africa
LESSONS LEARNED AND CHALLENGES IN COVID-19 VACCINE TRIALS
(ABSTRACT
74)
Kathleen Neuzil
University of Maryland School of Medicine, Baltimore, MD, USA
EQUITABLE ROLL-OUT OF COVID-19 VACCINES IN THE UNITED STATES
(ABSTRACT
75)
Michelle Williams
Harvard T.H. Chan School of Public Health, Boston, MA, USA
VACCINE ACCEPTANCE
(ABSTRACT
76)
Saad Omer
Yale University, New Haven, CT, USA
GLOBAL DISTRIBUTION OF THE SARS-COV-2 VACCINE
(ABSTRACT
77)
Nicole Lurie
Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
HEPATITIS C ELIMINATION: WHAT'S TAKING SO LONG?
(ABSTRACT
70)
Annie Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
MECHANISMS AND TREATMENTS OF STEATOSIS IN HIV
(ABSTRACT
71)
Steven Grinspoon
Harvard Medical School, Boston, MA, USA
HARNESSING IMMUNITY TO CURE HBV
(ABSTRACT
72)
Ulrike Protzer
Technical University of Munich, Munich, Germany
NEW PROSPECTS FOR THE TREATMENT OF HBV
(ABSTRACT
73)
Heiner Wedemeyer
Hannover Medical School, Hannover, Germany
SYMPOSIUM CONVENER
Dennis L Kolson
University of Pennsylvania, Philadelphia, PA, USA
NOVEL FINDINGS OF NEURONAL MODULATION OF HIV EXPRESSION IN MICROGLIA
(ABSTRACT
62)
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
ROLE OF CNS CD4 T CELLS AND MACROPHAGES IN SIV NEUROPATHOGENESIS AND RESERVOIRS
(ABSTRACT
63)
Vanessa M Hirsch
National Institutes of Health, Bethesda, MD, USA
MYELOID CNS HIV RESERVOIRS...THE DEBATE CONTINUES
(ABSTRACT
64)
Lishomwa Ndhlovu
Weill Cornell Medicine, New York, NY, USA
LESSONS FROM CNS HIV ESCAPE AND ATI FOR UNDERSTANDING HIV PERSISTENCE IN THE CNS
(ABSTRACT
65)
Sarah B Joseph
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
|
<< first | < prev
page:
of 7
|
records per page:
next > | last >>
|
|
pages:
1
2
3
4
5
6
7
|
presentations:
1 to
50 of
337
|
